Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Imatinib in Desmoid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological confirmed aggressive fibromatosis (desmoid tumor)~* Measurable disease according to the RECIST criteria~* Evidence of relapse or disease progression within the last 6 months (based on RECIST criteria) in computed tomography or magnetic resonance imaging~* No possibility of complete surgical resection or cases in which surgical therapy leaving a large tissue defect, functional deficit or disfigurement would be required~* No possibility of curative radiotherapy with acceptable toxicity and/or late morbidity~* Previous treatment of the tumor region by surgical intervention and/or radiotherapy and/or antihormonal therapy possible~* Age \> or = 18 years~* WHO PS \< or = 1~* Effective contraception during study medication~* Signed informed consent form~Exclusion Criteria:~* Surgical intervention \< 4 weeks~* Prior therapy with imatinib~* Pregnancy or lactation~* Severe hepatic dysfunction~* Known allergic reaction to imatinib or one of its components~* The following laboratory values: Absolute neutrophil count \< 1.5 x 103/mm3, Platelets \< 100,000/mm3, Serum creatinine \> or = 2.5 mg/dl, SGOT and/or SGPT \> 2.5 x ULN (upper limit of normal), Total bilirubin \> 1.5 x ULN~* Participation in another study (four weeks before and during the study)~* Prior malignancy apart from completely resected basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- drug (Type: EXPERIMENTAL): Imatinib 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).